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Abstract Peroxiredoxin 6 is an antioxidant enzyme and is
the 1-cys member of the peroxiredoxin family. Using two-
dimensional electrophoresis and Western blotting, we have
shown for the Wrst time that, in human control and brain tis-
sue of patient’s with Alzheimer’s disease (AD), this
enzyme exists as three major and Wve minor forms with pIs
from 5.3 to 6.1. Using speciWc cellular markers, we have
shown that peroxiredoxin 6 is present in astrocytes with
very low levels in neurons, but not detectable in microglia
or oligodendrocytes. In control brains, there was a very low
level of peroxiredoxin 6 staining in astrocytes that was con-
Wned to a “halo” around the nucleus. In AD, there were
marked increases in the number and staining intensity of
peroxiredoxin 6 positive astrocytes in both gray and white
matter in the midfrontal cortex, cingulate, hippocampus and
amygdala. Confocal microscopy using antibodies to A
peptide, tau and peroxiredoxin 6 showed that peroxiredoxin
6 positive astrocytes are closely involved with diVuse
plaques and to a lesser extent with neuritic plaques, sug-
gesting that plaques are producing reactive oxygen species.
There appeared to be little astrocytic response to tau
containing neurons. Although peroxiredoxin 6 positive
astrocytes were seen to make multiple contacts with tau
positive neurons, there was no intraneuronal colocalization.
In brain tissue of patients with AD, many blood vessels
exhibited peroxiredoxin 6 staining that appeared to be due
to the astrocytic foot processes. These results suggest that
oxidative stress conditions exist in AD and that peroxire-
doxin 6 is an important antioxidant enzyme in human brain
defenses.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized by the progressive decline in memory, lan-
guage, cognition and motor functions. The neuropathologi-
cal hallmarks of AD are the accumulation of extracellular
amyloid plaques containing the amyloid beta peptide (A)
and intraneuronal neuroWbrillary tangles containing hyper-
phosphorylated microtubule-associated protein tau.
Although the initiating molecular event(s) in AD are not
known, oxidative stress produced by the generation of reac-
tive oxygen species (ROS) appears to be a fundamental
process contributing to the neuropathophysiology [10].
Whether oxidative stress has a role in the cause or aVect in
AD has been debated for many years, but recent research
has suggested that it occurs prior to the onset of symptoms
[35]. The histopathological evidence for oxidative stress in
AD includes lipid, protein and DNA oxidation. There is
evidence to suggest that oxidative stress is generated
peripherally [26] with the brain being particularly suscepti-
ble, but there is also a body of evidence to suggest that
amyloid  peptide (A42) may be linked to lipid peroxida-
tion [5, 6], which may then be linked to the phosphorylation
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of tau [24]. Two reactive products of A42-induced lipid
peroxidation are the production of four hydroxynonenal
and acrolein [5], which have been shown to disrupt mem-
brane asymmetry [7] and may be involved in the conforma-
tional changes to tau, promoting the formation of
neuroWbrillary tangles [24].
Oxidative damage occurs as part of the aging process,
but it occurs at a much greater rate in most neurodegenera-
tive diseases [3]. The hallmark of protein oxidation is the
generation of protein carbonyls, which are markedly ele-
vated in AD [3, 16]. There is overwhelming evidence to
implicate oxidative stress in the pathogenesis of AD, and
this is most likely an early event in the disease process.
Less is known however of how the brain responds to oxida-
tive insults. There are a number of cellular antioxidant
defenses whose primary role is to convert the ROS into
unreactive compounds. These defense mechanisms include
superoxide dismutase, which works together with sele-
nium-dependent glutathione peroxidase, catalase and more
recently the peroxiredoxin family. These enzymes trans-
form the superoxide radical to hydrogen peroxide, which in
turn is converted to water. The distribution and changes in
expression of the antioxidant enzymes have not been well
studied as the other aspects of the disease process.
Cellular selenium-dependant glutathione peroxidase
(GPx-1) has long been regarded as the major cellular anti-
oxidant enzyme, but there are conXicting reports regarding
the changes in activities of this enzyme in AD. Early
reports suggest that there is no change in GPx-1 activities in
AD brains [15,  20], while other researchers suggest that
there is a decrease in GPx-1 activity [8, 27, 32]. There are
no reports indicating compensatory increase in GPx-1
activity; however, cell models overexpressing GPx-1 are
more resistant to A-mediated toxicity, suggesting that
increased levels of GPx-1 is protective [2].
There is considerable evidence to implicate A toxicity
and the generation of ROS and in particular hydrogen perox-
ide as key steps in contributing to the neurotoxicity in AD.
We have previously reported that peroxiredoxin 6, also
termed 1 Cys-peroxiredoxin or nonselenium glutathione
peroxidase, is upregulated in Parkinson’s disease (PD) [30].
This enzyme has no amino acid homology to any known
sequence of the glutathione peroxidase enzymes and has
both antioxidant and phospholipase A2 activity and can
reduce hydroxyperoxides [9]. Given that the brain is particu-
larly vulnerable to oxidative damage due to its high energy
and oxygen requirements, high levels of transition metals
and peroxidizable fatty acids suggests that peroxiredoxin 6
could play a key antioxidant role in neuroprotection.
There are six members of the peroxiredoxin family at
this stage with peroxiredoxins 1–5 being the 2-Cys mem-
bers while peroxiredoxin 6 is the sole 1-Cys member [36].
This enzyme is bifunctional with 80% of its function as a
peroxidase and the remainder as a phospholipase A2. Per-
oxiredoxin 6 has not speciWcally been examined in brain
tissue of AD patients, and the aims of this study are to
examine the molecular forms, cellular distribution and
association with AD pathology. This study focused on the
cingulate, amygdala, hippocampus and cortical regions in




Peroxiredoxin 6 (rabbit) was obtained from Antibody Tech-
nology Australia Pty, Ltd, Adelaide, Australia. Tau (mouse)
was obtained from Novacastra Laboratories Ltd, Newcastle,
UK. Tau (goat) was obtained from Santa Cruz Biotechnol-
ogy Inc., California, USA. Amyloid beta (mouse) was
obtained from Novacastra Laboratories Ltd, Newcastle, UK.
Glial Wbrillary acidic protein (GFAP) (mouse) was obtained
from Novacastra Laboratories Ltd, Newcastle, UK. Human
neuronal protein HuC/HuD (mouse) was obtained from
Molecular Probes Inc., Eugene, USA. Human HLA (MHC2)
(mouse) was obtained from Dakocytomation, Denmark A/S.
Myelin basic protein (MBP) (mouse) was obtained from
Novacastra Laboratories Ltd, Newcastle, UK.
Secondary antibodies
Donkey anti sheep Cy3 was obtained from Jackson Immu-
noresearch, West Grove, USA. Donkey antirabbit Cy3 and
Cy5 were obtained from Jackson Immunoresearch, West
Grove, USA. Goat antimouse Alexa 488 was obtained from
Molecular Probes Inc., Eugene, USA. Goat antirabbit alka-
line phosphatase was obtained from Sigma Chemical Com-
pany, St Louis, USA.
Brain tissue
The brain tissue was obtained from the National Health and
Medical Research Council South Australian Brain Bank.
Brains were removed at autopsy from clinically diagnosed
AD cases and conWrmed pathologically postmortem. The
control cases were obtained from people who died of unre-
lated causes without diagnosed neurological pathology that
was conWrmed postmortem. The brains were bisected and
one half snap-frozen at ¡80°C and the other immersion
Wxed in buVered formaldehyde. Tissue blocks were pro-
cessed and embedded in paraYn and 8 m sections were cut
and mounted onto gelatin-coated slides. Table 1 provides a
list of the brain regions examined and the case details.Acta Neuropathol (2008) 115:611–622 613
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Brain homogenate
Frozen tissue from midfrontal cortex of three AD brains
and three control cases were homogenized in 50 mM Tris,
5 mM EDTA, 0.1% sodium azide, 1 l/ml pepstatin and
leupeptin and 0.3 mM of phenylmethylsulfonyl Xuoride.
Five milliliters of homogenization buVer was used per gram
of brain tissue and homogenized using six passes of a
motorized Wheaton TeXon pestle tissue grinder. Homoge-
nates were centrifuged (500£g) for 10 min to remove par-
ticulate matter and snap-frozen at ¡80°C. Table 2 provides
the details of these cases.
Sample preparation
Aliquots (100 l) of Alzheimer’s and control brain homog-
enates underwent a 2D clean up as per the Amersham Bio-
sciences protocol. The samples were then resolubilized in
300 l of TUC pH 4–7 buVer containing 7 M urea, 2 M
thiourea, 4% CHAPS, 0.5% dithiothreitol, 0.5% IPG buVer
pH 4–7. Samples were then assayed for total protein con-
tent. Prior to rehydration of the immobilized pH gradient
strips, trace amounts of bromophenol blue was added to
samples. Table 2 provides a list of cases used in the 2D
electrophoresis.
2D polyacrylamide gel electrophoresis (PAGE)
Isoelectric focusing
Isoelectric focusing was performed on 13 cm immobilized
pH gradient strips (pH 4–7NL, Amersham Pharmacia)
using an IPGphor (Amersham Pharmacia) isoelectric focus-
ing unit. Samples were applied in gel rehydration (50 V,
overnight) using 7 M urea, 2 M thiourea, 4% CHAPS, 0.5%
dithiothreitol, 0.5% pharmalyte pH 4–7 with a trace of bro-
mophenol blue as the re-swell buVer with a total loading
volume of 280 l including sample. Stained gels received a
400 g protein load and Western blotting gels received a
200 g load. IEF was performed for »60 kV h (500 V
30 min, 1,000 V 30 min, 1,000–8,000 V 30 min, 8,000 V
5–7 h, 1,000 V hold to end).
Table 1 List of cases used in cell counting
PMI postmortem index, AD Alzheimer’s disease, NIA Reagan high or low likely-hood of AD, M male, F female, C cingulate, A amygdala, H hip-
pocampus, MC midfrontal cortex, C control, ADL adeno lung carcinoma, Unk unknown, CF cardiac failure, SS septic shock, DM disseminated
malignancy, HVD hypertensive vascular disease
Case number Sex Age (years) Diagnosis Region PMI (h) Braak stage NIA Reagan
AD1 M 65 AD C, A, H, MC  3 5/6 High
AD2 F 84 AD C, A, H, MC  16 5/6 High
AD3 M 63 AD C, A, H, MC  33 5/6 High
AD4 M 59 AD C, A, H, MC 20 5/6 High
AD5 F 81 AD C, A, H, MC 19 5/6 High
AD6 F 69 AD C, A, H, MC 38 5/6 High
C1 F 79 ADL C, A, H, MC 4 Low
C2 M 69 Unk C, A, H, MC 48 Low
C3 F 61 CF C, A, H, MC 8 Low
C4 F 84 SS C, A, H, MC 15 Low
C5 F 86 DM C, A, H, MC 17 Low
C6 F 86 HVD C, A, H, MC 6 Low
Table 2 List of cases used for 2D PAGE and Western blots
PMI postmortem index, AD Alzheimer’s disease, F female, M male, MC midfrontal cortex, C control, HVD hypertensive vascular disease, ABD
anoxic brain damage, SS septic shock
Case number Sex Age (years) Diagnosis Region PMI (h) Braak stage NIA Reagan
AD7 F 69 AD MC 22 5/6 High
AD8 F 79 AD MC 18 5/6 High
AD9 F 76 AD MC 23 5/6 High
C6 F 86 HVD MC 6 Low
C7 F 73 ABD MC 24 Low
C8 M 63 SS MC 38 Low614 Acta Neuropathol (2008) 115:611–622
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SDS PAGE
SDS PAGE was performed using 12.5% acrylamide gels.
Immobilized pH gradient strips were incubated in SDS
equilibration buVer containing 1% w/v dithiothreitol for
15 min followed by SDS equilibration buVer containing 4%
w/v iodoacetamide for 15 min. Strips were then placed
above the second dimension gels and overlaid with 1% low
melting point agarose in Tris glycine gel running buVer.
Electrophoresis was performed at 350 V for 2.5–3 h at
10°C. Protein gels were visualized using SYPRO ruby Xuo-
rescent stain (incubated for 2 h) and scanned using a
Typhoon 9400 Variable Mode Imager (Amersham Biosci-
ences).
Western blotting
Separated proteins were transferred onto low Xuorescence
PVDF membrane by semi-dry electroblotting at 0.8 mA/
cm2 for 2 h. After blocking, the membranes were incubated
in aYnity-puriWed rabbit antiperoxiredoxin 6 antibodies (1/
2,000) overnight at 4°C followed by goat antirabbit alkaline
phosphatase antibodies (1/10,000) (Sigma) for 1 h and
visualized using ECF substrate and a Typhoon 9400 Vari-
able Mode Imager.
Immunohistochemistry
Localization of peroxiredoxin 6
Immunohistochemical staining of AD and control tissue
was carried out as previously described [30]. The cellular
distribution of peroxiredoxin 6 was compared with the
staining obtained with antibodies to speciWc cellular mark-
ers. Antibodies to GFAP (astrocytes), HLA (MHC2)
(microglia), MBP (oligodendrocytes) and HuC/HuD (neu-
rons) were used to map the distribution of peroxiredoxin 6.
Colocalization of peroxiredoxin 6, A and Tau
Brain sections were incubated with rabbit antiperoxire-
doxin 6, mouse anti A peptide and goat anti tau antibodies
overnight and detected with secondary antibodies conju-
gated to Xuorescent Xuorophores Cy5, Alexa 488 and Cy3,
respectively. Sections were examined using a Bio-Rad
Confocal laser scanning microscope and Bio-Rad software
package, as previously described [30].
Cell counting
Cell counting was carried out blind on masked sections,
and peroxiredoxin 6 positive astrocytes were counted at
20£ magniWcation with a graticule eye piece (0.0625 mm2)
using an Olympus HO-2 microscope on brain tissue from
six AD and six control cases. In each case, Wve regions
were randomly selected to give a uniform representation
of the white and gray matter in the cingulate, hippocam-
pus, amygdala and midfrontal cortex. The number of
positive cells from each of the Wve areas was averaged
and divided by the area of the graticule eyepiece and
expressed as cells/mm2. The data was then analyzed
using a one-way ANOVA that examined the interactions
listed in Table 3. The signiWcance was determined at 0.01
level of probability.
Table 3 Interactions examined 
in cell counting data
Interactions examined F value Critical F 
(P =0 . 0 1 )
SigniWcance 
(>0.01)
Are there diVerences in AD (C, A, H, MC) 
gray matter cell counts?
1.00 4.94 NS
Are there diVerences in AD (C, A, H, MC) 
white matter cell counts?
1.23 4.94 NS
Are there diVerences in control (C, A, H, MC) 
gray matter cell counts?
0.62 4.94 NS
Are there diVerences in control (C, A, H, MC) 
white matter cell counts?
0.25 4.94 NS
Are there diVerences between gray and white 
matter cell counts in AD tissue?
89.3 7.21 S
Are there diVerences between gray and white 
matter cell counts in control tissue?
14.5 7.21 S
Are there diVerences in gray matter cell counts 
between control and AD tissue?
299 7.21 S
Are there diVerences in white matter cell counts 
between control and AD tissue?
28.0 7.21 S
AD Alzheimer’s disease, NS not 
signiWcant, S signiWcant, C cin-
gulate, A amygdala, H hippo-
campus, MC midfrontal cortexActa Neuropathol (2008) 115:611–622 615
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Results
Molecular forms of peroxiredoxin 6 in human brain
We have previously shown that this antibody is speciWc for
a 26 kDa monomer in rat lung and human brain, and the N-
terminal sequence is identical to peroxiredoxin 6 [30, 31].
Two-dimensional PAGE and Western blotting of AD and
control brain homogenates indicated that this protein exists
as three major and Wve minor forms as shown in Fig. 1a–d.
Although the loadings were consistent, the Wve minor forms
could not be detected on all gels. For comparison, the spots
were labeled 1–8 (Fig. 2).
The respective pIs of the eight forms are 5.3, 5.4, 5.6,
5.75, 5.85, 5.9, 5.95 and 6.1. The three major forms were 3,
6 and 7 and the average pIs of these were 5.59, 5.88 and
5.96 for AD tissue and 5.59, 5.80 and 5.86 for control tis-
sue. These major forms were consistent in all homogenates.
The intensity of the three major forms was analyzed using
the Typhoon imager and the intensity of spots 6 and 7 was
Fig. 1 a, b A two-dimensional 
PAGE gel and blot of AD brain 
tissue (Case AD7) and a corre-
sponding control brain gel and 
blot panels (c, d) (Case C7). pI 
4–6 is indicated between the gel 
and blots and the molecular 
weight of the standards (Std) in 
kilo Daltons is shown on the Y-
axis. The gels were stained with 
SYPRO ruby Xuorescent stain. 
The box indicates the location of 
the molecular forms of peroxire-
doxin 6. Some spots are shown 
on the blots to indicate the range 
of peroxiredoxin 6 pIs
Fig. 2 A composite Wgure at 
higher magniWcation showing 
the range of molecular forms in 
three cases of AD tissue (a AD7, 
AD8 and AD9) and three cases 
of control tissue (b C7, C6 and 
C8). The range of molecular 
forms 1–8 is shown, but not all 
forms are present in all cases. 
Although there are slight varia-
tions between blots, the respec-
tive pIs are as follows: 1 (5.3), 2 
(5.4), 3 (5.6), 4 (5.75), 5 (5.85), 
6 (5.9), 7 (5.95), 8 (6.1)616 Acta Neuropathol (2008) 115:611–622
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reversed in the AD and control homogenates (Fig. 2).
Minor forms 1 and 2 were present in AD homogenates but
absent in the control tissue, while minor form 8 was present
in control tissue but absent in AD tissue (Fig. 2).
Cellular distribution of peroxiredoxin 6 in control and AD 
brain tissue
Using immunohistochemical markers for speciWc human
brain cell types, we have shown that peroxiredoxin 6 is
abundant in reactive astrocytes (Fig. 3a–c) in AD tissue and
present in very low levels in neurons (Fig. 3j–l). We were
not able to detect peroxiredoxin 6 in either microglia
(Fig. 3d–f) or oligodendrocytes (Fig. 3g–i).
There was a marked contrast between the staining of
control and reactive astrocytes in AD. Reactive astrocytes
in AD were hypertrophied with abundant staining of perox-
iredoxin 6, while in control astrocytes the staining was con-
Wned to a “halo” around the nucleus (Fig. 4). The increased
staining of peroxiredoxin 6 was seen in all regions exam-
ined and in both gray and white matter, but the staining was
not evenly distributed and some regions on the same sec-
tion were heavily labeled but adjacent regions showed little
staining (Fig. 5).
Fig. 3 Confocal localization of 
peroxiredoxin 6 (P6) with GFAP 
(astrocyte marker) (a P6, Cy2-
green; b GFAP, Cy3-red; c 
merged image; bar 25 M), 
MHC2 (microglia marker) (d 
P6, Cy2-green; e MHC2, Cy3-
red; f merged image; 
bar 25 M), MBP (oligodendro-
cyte marker) (g P6, Cy2-green; 
h MBP, Cy3-red; i merged im-
age; bar 10 M), Hu (neuronal 
marker) (j P6, Cy2-green; k Hu, 
Cy3-red; l merged image; 
bar 25 M). Cell localization 
was performed using AD tissueActa Neuropathol (2008) 115:611–622 617
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Cell counting
In AD and control tissue, peroxiredoxin 6 was colocalized
with GFAP, indicating that the upregulation is occurring in
astrocytes, which is similar to what was found in PD and
dementia with Lewy bodies [30]. Cell counting was conducted
on midfrontal cortex, cingulate, amygdala and hippocampus
brain regions and in gray and white matter to determine if spe-
ciWc areas or matter type were speciWcally aVected. These are
summarized in Fig. 6. A one-way ANOVA was performed
comparing the cell counts between AD and control tissue in
diVerent regions by tissue and matter type. The results of the
interactions examined are shown in Table 3.
Colocalization of peroxiredoxin 6 and AD pathology
The major deWning pathology in AD is the presence of
extracellular plaques and intracellular hyperphosphorylated
tau in the form of tangles. Plaques are present in brain tis-
sue at diVerent stages of development, ranging from diVuse
plaques to Wbrillar and neuritic plaques. It is generally con-
sidered that diVuse plaques do not contain tau, but neuritic
plaques contain both A and tau. Colocalization of perox-
iredoxin 6 and the A peptide, a major component of
plaques, and tau was carried out to determine if peroxire-
doxin 6 positive astrocytes were associated with AD
pathology.
Fig. 4 Oil immersion image 
(£1,000) of typical astrocyte 
seen in AD cortex (a) and in 
control cortex (b)
Fig. 5 Light immunohisto-
chemistry (DAB substrate) of 
peroxiredoxin 6 staining of 
astrocytes in AD gray matter (a), 
AD white matter (b), control tis-
sue gray matter (c) and control 
tissue white matter (d). All im-
ages at £200 magniWcation618 Acta Neuropathol (2008) 115:611–622
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Tau pathology
Tau deposits in the form of neuroWbrillary tangles were
observed in many neurons and neurites, and were often sur-
rounded by peroxiredoxin 6 astrocytes, which made multi-
ple contacts (Fig. 7a–c). Although astrocytes made many
contacts with neurons, most neurons had very low levels of
peroxiredoxin 6 and it did not appear to be upregulated or
to be colocalized with tau in AD.
Plaques
DiVuse plaques contained strongly stained aggregations
of A peptide. Peroxiredoxin 6 staining was conWned to
astrocytes and their projections that were in close proxim-
ity to plaques (Fig. 7d–h). Some astrocytes were observed
within plaques, but generally the astrocyte cell bodies
were on the periphery with their processes projecting into
the plaques. Some plaques contained the beginnings of a
dense core of amyloid and took on a “wagon wheel”
appearance (Fig. 7i, j). DiVuse plaques and those with A
beginning to aggregate appeared to elicit a stronger perox-
iredoxin 6 astrocytic response than those with a dense
core of A.
Peroxiredoxin 6 staining of blood vessels
In many regions of the AD brain, there appeared to be
strong peroxiredoxin 6 staining in the walls of many blood
vessels, which could be seen to have multiple contacts with
strongly staining activated astrocytes (Fig. 7k).
Discussion
Peroxiredoxin 6, also known as 1-Cys peroxiredoxin or
non-selenium glutathione peroxidase, is a human brain
antioxidant enzyme that is abundant in activated astro-
cytes and present in low levels in neurons. On exposure to
hydrogen peroxide, the N-terminal peroxiredoxin 6 corre-
sponding to Cys 47 is readily oxidized, but as yet its redox
partner has not been identiWed. Glutathione, lipoic acid
and cyclophilin have all been implicated [13, 23, 29]. In
addition to its peroxidase activity, peroxiredoxin 6 also
has phospholipase A2 activity that might be signiWcant in
the brain, which has a high lipid content [9]. Peroxire-
doxin 6 staining of astrocytes is markedly elevated in
many brain regions in PD and dementia with Lewy bodies
[30]. We now show that it is upregulated in the astrocytes
in AD and describe for the Wrst time the range of molecular
forms of peroxiredoxin 6 in human brain in both control
and AD tissue.
Three major variants and Wve minor forms were identi-
Wed with pIs ranging from 5.3 to 6.1. There were three
major diVerences in the peroxiredoxin 6 variants between
control and AD tissue. The AD tissue had the two more
acidic forms 1 and 2 that were not present in control tissue;
the intensity of the major forms 6 and 7 were reversed
between AD and control tissue and minor form 8 was
absent in AD tissue. We can only speculate on the signiW-
cance of these Wndings at this stage, but diVerent forms may
have diVerent aYnities for diVerent substrates that might be
more abundant under various pathological conditions or the
more acidic forms are the result of oxidation [11]. At this
stage, we cannot determine whether these diVerences are
true isoforms or post-translational modiWcations of the
same protein, but would suspect the latter. These Wndings
are in agreement with two previous proteomic studies in an
AD mouse model and in human brain AD tissue, which
reported elevated levels of peroxiredoxin 6 [33,  34]. A
more recent study using PC12-resistant and PC12 cells
treated with A also reported increased levels of peroxire-
doxin 6 [11]. A-treated cells contained an extra acidic
form, which was suggested to be the result of oxidation of
the catalytic cysteine to a sulfenic, sulWnic or sulfonic
derivative. We found two minor acidic forms in AD tissue,
which is also consistent with this report.
Tissue selection is also a variable that needs to be con-
sidered. While the AD tissue had all the hallmarks of AD
pathology and was easy to deWne, age-matched control tis-
sues are somewhat more variable. All the control tissue was
from people without clinically deWned AD, but most brains
in this age group usually contain some neurodegenerative
pathology. The age span of the two groups was similar,
59–84 years for the AD group and 61–86 years for the con-
Fig. 6 A bar chart showing the range of cell counts in diVerent brain
regions in gray and white matter in control tissue and in AD tissue. WM
white matter, GM gray matter, Cing cingulate, Amy amygdala, MFC
midfrontal cortex, Hip hippocampus. Counts are shown as mean § SE,
N = 6 in all casesActa Neuropathol (2008) 115:611–622 619
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trol group, but the mean age for the control group was
7 years older. We feel conWdent that, although some control
tissue may have had some elements of subclinical AD
pathology, the reduced level of astrocyte activation and the
clear diVerences in the cell counting would indicate that all
the control tissues were not experiencing high levels of oxi-
dative stress as compared to the AD tissue.
Previously, we had shown that peroxiredoxin 6 was
abundant in astrocytes in PD and dementia with Lewy body
tissue [30]. We have now used cellular markers to other brain
cell types to show that in addition to astrocytes there is a low
level in the cytoplasm of most neurons. Unlike astrocytes,
neurons do not appear to have increased peroxiredoxin 6
staining in AD tissue. We could not detect any peroxiredoxin
6 staining in microglia or oligodendrocytes.
Cell counting of peroxiredoxin 6 positive astrocytes
indicated that there was a marked increase in both the gray
and white matter in AD tissue compared with control tis-
sue. Gray matter had more peroxiredoxin 6 positive astro-
cytes than white matter in both AD and control tissue, and
this diVerence was more pronounced in AD tissue with F
values of 89.0 and 14.5, respectively. Considering that the
major pathology (plaques and tangles) is located in the
gray matter, it would be expected that oxidative stress is
Fig. 7 a–c Confocal localiza-
tion of tau within neurons (a 
Cy2-green) and peroxiredoxin 6 
positive astrocytes (b Cy3-red) 
and (c) the merged image in AD 
brain tissue (bar =1 0M). d–f 
Confocal localization of A pep-
tide (d Alexa 488, green) and 
peroxiredoxin 6 positive astro-
cytes (e Cy3-red) and (f) the 
merged image in a diVuse plaque 
in AD brain tissue 
(bar =5 0M). g–j Confocal 
localization of A peptide (Al-
exa 488, green) and peroxire-
doxin 6 positive astrocytes 
(Cy5-light blue) in four diVerent 
plaques in AD brain tissue 
(bar =5 0M). k Immunohisto-
chemical staining (DAB sub-
strate) showing peroxiredoxin 6 
staining of astrocytes and astro-
cyte foot processes in the walls 
of blood vessels in the midfron-
tal cortex in Alzheimer’s disease 
(£400). Arrows indicate perox-
iredoxin 6 positive astrocytic 
processes620 Acta Neuropathol (2008) 115:611–622
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more pronounced in this area. Cell counting indicated
that the peroxiredoxin 6 positive astrocyte numbers were
elevated in all regions examined, suggesting that the insult
activating astrocytes is wide spread and not conWned to
any speciWc region in either the gray or white matter.
Indeed, extracellular plaques were observed in all regions
examined in AD tissue. Although all regions examined
showed astrocyte activation, this was not uniformly dis-
tributed through all areas, with some areas showing exten-
sive astrocyte activation while adjacent areas were similar
to controls.
There are two deWning pathologies in AD. These are the
presence of extracellular plaques comprising abundant
deposits of A peptides, which later aggregate to form
amyloid [25] and intracellular hyperphosphorylated tau
aggregations in the form of paired helical Wlaments, which
are termed tangles [14, 22]. The two well-described forms
of plaques have been termed diVuse plaques and neuritic or
senile plaques [12, 18], although other intermediate forms
such as Wbrillar plaques have been described [12]. DiVuse
plaques are spherical structures of less dense A deposits
and are considered an early stage of plaque formation. In
diVuse plaques, aggregations of A exists as nonamyloid
deposits, but as the plaque progresses, the A and other
protein aggregations change from the normal conformation
into a -sheet structure, termed amyloid, and take up spe-
ciWc dyes like Congo red and thioXavin [4]. These plaques
do not generally contain tau; however, in many confocal
images, diVuse plaques contain focal points of tau, which
are probably enlarged neurites. Neuritic or senile plaques
contain a dense core of amyloid enriched with A peptide
with a corona of less dense amyloid. The diVuse plaques
appeared to elicit a stronger astrocytic response based on
the level of peroxiredoxin 6 staining than the neuritic
plaques. Our images suggest that once the A forms amy-
loid and condenses, it is less stimulating toward astrocytes
and perhaps the formation of amyloid is a protective mech-
anism to inactivate the toxicity of soluble A. These obser-
vations are consistent with the Wndings of Kawaguchi-
Niida et al., who reported that the highly reactive carbonyl
crotonaldehyde generated during lipid peroxidation is
localized to reactive astrocytes, microglia and diVuse
plaques but undetectable in amyloid cores [19].
Although the activation of astrocytes and upregulation
of peroxiredoxin 6 would be considered a protective
response, in cell culture, soluble A has been shown to
stimulate nitric oxide synthetase and the production of
nitric oxide, which is very damaging to neurons [17]. This
response is further upregulated by other inXammatory
cytokines such as interleukin 1 and tumour necrosis fac-
tor-, which are reported to be released from astrocytes
[1]. At this stage, we are not sure of the net beneWt to neu-
ral tissue of activated astrocytes with elevated levels of
peroxiredoxin 6, concomitant with the increased produc-
tion of nitric oxide.
NeuroWbrillary tangles comprising hyperphosphorylated
tau were observed in many regions in AD tissue. Two anti-
bodies were used to localize tau, a monoclonal antibody
(Novacastra) and one speciWc for paired helical Wlaments
(Santa Cruz) and both produced a similar staining pattern.
Neurons containing tau were not surrounded by activated
astrocytes as were the diVuse plaques and to a lesser extent
the neuritic plaques, suggesting that these cells are not
secreting toxic or activating products that are stimulating to
astrocytes. In PD, Lewy bodies contained a dense core of
peroxiredoxin 6 staining suggesting that it was trying to
detoxify oxidative stress produced by Lewy bodies, but we
did not observe any interaction between tau and peroxire-
doxin 6 in AD tissue. Although there is considerable evi-
dence to implicate oxidative stress in the
hyperphosphorylation of tau, this does not appear to upreg-
ulate peroxiredoxin 6 in tau positive neurons.
In some regions, the walls of blood vessels exhibited
strong peroxiredoxin 6 staining, which also elicited a
strong astrocytic response in surrounding astrocytes.
These activated astrocytes had many processes in contact
with the endothelial cells. Although vascular amyloid
deposits were seen in some sections and is a key feature of
AD [28], the upregulation of peroxiredoxin 6 appeared to
occur in regions without distinct A staining. A has been
shown to induce vascular vasoconstriction in rat skin,
which can be reversed by superoxide dismutase and cata-
lase, indicating that A is capable of generating ROS
within blood vessels [21]. The blood brain barrier consists
of the capillary endothelial cells, and the foot processes of
the astrocytes and the fused basal lamina of both cells.
The peroxiredoxin 6 staining within the capillaries
appears to be in the foot processes of the astrocytes.
Whether this increased staining is due to ROS generated
from within neural tissue or reXects a more systemic
pathology derived from the circulation is unclear.
In conclusion, we have shown for the Wrst time the
range of peroxiredoxin 6 variants, which are either iso-
forms or post-translational modiWcations in human brain
tissue. We have also shown that peroxiredoxin 6 is
primarily an astrocytic enzyme with very low levels in
neurons and is not detectable in microglia or oligodendro-
cytes. This enzyme is markedly elevated in astrocytes
in both white and gray matter in AD. Strongly staining
peroxiredoxin 6 astrocytes appear to be involved in the
detoxiWcation of diVuse plaques and to a lesser extent in
neuritic plaques, but is not associated with tau aggrega-
tions within neurons. From this work and previous work
on PD and dementia with Lewy bodies, we suggest that
peroxiredoxin 6 is a major antioxidant enzyme in human
neural tissue.Acta Neuropathol (2008) 115:611–622 621
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